Document Detail


Cardiovascular autophagy: crossroads of pathology, pharmacology and toxicology.
MedLine Citation:
PMID:  23408289     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiovascular disease (CVD) remains the leading cause of death worldwide, despite the significant advances in medicine. Autophagy, a process of self-cannibalization employed by mammalian cells for the recycling of cellular contents, is altered not only in a number of CVDs, but in other diseases, as well. Many FDA-approved drugs are known to induce autophagy-mediated side effects in the cardiovascular system. In some cases, such drug-induced autophagy could be harnessed and used for treating CVD, greatly reducing the duration and cost of CVD treatments. However, because the induction of autophagy in cardiovascular targets can be both adaptive and maladaptive under specific settings, the challenge is to determine whether the changes stimulated by drug-induced autophagy are, in fact, beneficial. In this review, we surveyed a number of CVDs in which autophagy is known to occur, and we also address the role of FDA-approved drugs for which autophagy-mediated side effects occur within the cardiovascular system. The therapeutic potential of using small molecule modulators of autophagy in the management of CVD progression is discussed.
Authors:
Joshua K Salabei; Daniel J Conklin
Related Documents :
17209799 - Non-nicotinic therapies for smoking cessation.
12866419 - Clinical development of therapeutic recombinant proteins.
16052239 - Industry funding of the fda: effects of pdufa on approval times and withdrawal rates.
2980359 - Food and drug administration guidelines for reproductive toxicity testing.
11263849 - Phenylpropanolamine and stroke: the study, the fda ruling, the implications.
19659819 - Publication bias perpetuates use of ineffective drugs in stroke.
19631739 - New amphiphilic and ph-sensitive hydrogel for controlled release of a model poorly wate...
22136259 - Controlled release pulmonary administration of curcumin using swellable biocompatible m...
1583409 - Development of a therapeutic procedure for bismuth intoxication with chelating agents.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Cardiovascular toxicology     Volume:  13     ISSN:  1559-0259     ISO Abbreviation:  Cardiovasc. Toxicol.     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-09-10     Completed Date:  2014-04-02     Revised Date:  2014-09-02    
Medline Journal Info:
Nlm Unique ID:  101135818     Medline TA:  Cardiovasc Toxicol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  220-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Autophagy / drug effects*,  physiology*
Cardiovascular Agents / pharmacology
Cardiovascular Diseases / chemically induced,  drug therapy*,  pathology*
Cardiovascular System / drug effects*,  pathology*
Humans
Myocardium / pathology
Grant Support
ID/Acronym/Agency:
HL89380/HL/NHLBI NIH HHS; P20 RR024489/RR/NCRR NIH HHS; R01 HL055477/HL/NHLBI NIH HHS; R01 HL089380/HL/NHLBI NIH HHS; RR024489/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Cardiovascular Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma.
Next Document:  The subcortical auditory structures in the mongolian gerbil: II. Frequency-related topography of the...